Medicines Formulary - search results for ""

Search results for ""

Drug name	NICE TAs	Comments	Subchapter
Risperidone tablets		ESCA	4.2
Ritlecitinib	TA958 - Ritlecitinib for treating severe alopecia areata in people 12 years and over		13.5
Ritumixab infusion (Mabthera®, Truxima®)	TA195 - Drugs for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor		10.1
Rituximab	TA243 - Rituximab for the first-line treatment of stage III-IV follicular lymphoma TA193 - Rituximab for the treatment of relapsed or refractory chronic lymphocytic leukaemia TA174 - Rituximab for the first-line treatment of chronic lymphocytic leukaemia TA137 - Rituximab for the treatment of relapsed or refractory stage III or IV follicular non-Hodgkin's lymphoma TA65 - Rituximab for aggressive non-Hodgkin's lymphoma TA195 - Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor TA308 - Rituximab in combination with glucocorticoids for treating anti-neutrophil cytoplasmic antibody-associated vasculitis TA226 - Rituximab for the first-line maintenance treatment of follicular non-Hodgkin's lymphoma		8.2
Rivaroxaban tablets	TA170 - Venous thromboembolism - Rivaroxaban TA335 - Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome TA256 - Atrial fibrillation (stroke prevention) - Rivaroxaban TA261 - Venous thromboembolism (treatment and long-term secondary prevention) - Rivaroxaban TA287 - Pulmonary embolism and recurrent venous thromboembolism TA607 - Rivaroxaban for preventing atherothrombotic events in people with coronary or peripheral artery disease	Amber - specialist initation following diagnosis of AF- use in line with NICE. Initiation/ recommendation by a clinician who routinely initiates anticoagulants Amber - specialist initation for the treatment and secondary prevention of DVT and/or PE - use in line with NICE. Initiation/ recommendation by a clinician who routinely initiates anticoagulants. Where this is not the patient's GP, transfer to GP should be with the support of RICaD Amber - specialist initiation for preventing adverse outcomes after acute management of ACS use in line with NICE TA335. Initiation/recommendation by a clinician who routinely initiates anticoagulants. Where this is not the patient's GP, transfer to GP should be with the support of RICaD	2.8
Rivaroxaban tablets	TA170 - Venous thromboembolism - Rivaroxaban TA607 - Rivaroxaban for preventing atherothrombotic events in people with coronary or peripheral artery disease	BSSE APC preferred agent. This recommendation must only be taken into account after a patient and prescriber have discussed all treatment options (including warfarin) and only if they have no preference about which medicine they want to use. Red use following hip and knee surgery – full course of treatment supplied on discharge	2.8
Rivastigmine capsules	TA217 - Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease	Dementia drugs ESCA	4.11
Rivastigmine patches	TA217 - Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease	Dementia drugs ESCA	4.11
Rizatriptan tablets		Reserved for patients who are vomiting due to migraine	4.7
Rocuronium injection			15.1

First page
Previous page
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
Next page
Last page

Drug status key

Formulary drugs are allocated a traffic light status. This provides guidance on where clinical and prescribing responsibilities lie in regard to the initiation and maintenance of prescribing.

Grey

Positive NICE TA and/or awaiting local clarification on place in therapy. Please contact your medicines optimisation team for more information.

Red

Initiation and maintenance of prescribing by specialists only.

Amber

Initiation and maintenance of prescribing by specialists and transfer to primary care prescribing when appropriate, or in primary care following a specialists recommendation. Prior to initiation some medicines may require committee agreement or a framework to support safe transfer and maintenance.

Green

Initiation and maintenance of prescribing by specialists, GPs and other qualified clinicians.

Blue

Under review at University Hospitals Birmingham NHS Foundation Trust.